In this article, we will discuss Anlotinib (Therapeutic Efficacy-3). So, let’s get started.
Advanced STS
In recent years, an increasing number of targeted drugs have demonstrated good clinical efficacy in patients with certain histological types of advanced STS. These agents include multi-targeted kinase inhibitors, such as pazopanib, imatinib, sunitinib, and sorafenib; ALK inhibitors, such as crizotinib and ceritinib; anti-PDGFRs, such as the anti-PDGFRα monoclonal antibody olaratumab; and anti-angiogenic drugs, such as bevacizumab. However, pazopanib is the only small molecule TKI approved by the FDA for second-line STS treatment to date.